@entity1369 induces @entity296 and @entity32 via proinflammatory and profibrotic cytokines. The effect of @entity1482 on renal @entity32 and renal function was investigated in type 2 @entity6 @entity35 . For define the molecular mechanism of @entity1482 , the effect of @entity1482 on the synthesis of @entity657 ( @entity657 ) and its upstream transcription factor, NF-kappaB, was evaluated in cultured mesangial cells and proximal tubular cells. There were no changes in blood @entity413 concentration or BP after @entity1482 treatment. @entity1482 treatment significantly reduced urinary albumin excretion and ameliorated @entity631 . Urinary levels of @entity657 were significantly increased concurrently with renal expression of @entity657 , @entity23346 , and macrophage infiltration. @entity1482 treatment significantly inhibited urinary excretion of @entity657 as well as renal @entity657 and migration inhibitory factor expression and macrophage infiltration. In addition, @entity1369 induced upregulation of @entity657 expression and NF-kappaB transcriptional activity in cultured cells, and @entity1482 reduced both NF-kappaB activation and @entity657 synthesis. Furthermore, NF-kappaB inhibition abolished @entity1369 -induced @entity657 production. Overall, these findings suggest that @entity1369 -induced NF-kappaB activation leads to activation of proinflammatory cytokines, ultimately leading to @entity8 in this model. These data suggest that mineralocorticoid blockade may be a potential therapeutic target in @entity2316 .

@entity1482 prevents XXXX through an anti-inflammatory mechanism in type 2 @entity6 @entity35 .

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'vascular inflammation'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal injury'] @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial fibrosis'] @entity1369 :: ('MESH:D000450', 'Chemical') :: ['Aldosterone', 'aldosterone'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic'] @entity657 :: ('24770(Tax:10116)', 'Gene') :: ['monocyte chemotactic peptide-1', 'MCP-1'] @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetic nephropathy'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulosclerosis'] @entity1482 :: ('MESH:D013148', 'Chemical') :: ['spironolactone', 'Spironolactone'] @entity23346 :: ('103694877', 'Gene') :: ['macrophage migration inhibitory factor']
@entity2316 :: (MESH:D003928,Disease) :: ['diabetic nephropathy']
